Preclinical Evaluation of Antitumor Activity of the Proteasome Inhibitor MLN2238 (Ixazomib) in Hepatocellular Carcinoma Cells
Cell Death and Disease - United Kingdom
doi 10.1038/s41419-017-0195-0
Full Text
Open PDFAbstract
Available in full text
Date
January 18, 2018
Authors
Publisher
Springer Science and Business Media LLC